Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Publications

Found 16 results
Author Title [ Type(Desc)] Year
Filters: Keyword is Retrospective Studies  [Clear All Filters]
Journal Article
Verma HDev, Scherl EJanice, Jacob VElizabeth, Bosworth BPaul.  2011.  Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.. J Dig Dis. 12(5):379-83.
DeFilippis EM, Barfield E, Leifer D, Steinlauf A, Bosworth BP, Scherl EJ, Sockolow R.  2015.  Cerebral venous thrombosis in inflammatory bowel disease.. J Dig Dis. 16(2):104-8.
Cohen-Mekelburg S, Gold S, Schneider Y, Dennis M, Oromendia C, Yeo H, Michelassi F, Scherl E, Steinlauf A.  2019.  Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.. Dig Dis Sci. 64(1):196-203.
Yang E, Panaccione N, Whitmire N, Dulai PS, Casteele NVande, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R et al..  2020.  Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.. Aliment Pharmacol Ther. 51(11):1031-1038.
Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H et al..  2019.  Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.. Inflamm Bowel Dis. 25(4):775-781.
Cohen-Mekelburg S, Rosenblatt R, Gold S, Shen N, Fortune B, Waljee AK, Saini S, Scherl E, Burakoff R, Unruh M.  2019.  Fragmented Care is Prevalent Among Inflammatory Bowel Disease Readmissions and is Associated With Worse Outcomes.. Am J Gastroenterol. 114(2):276-290.
Cohen-Mekelburg S, Rosenblatt R, Gold S, Burakoff R, Waljee AK, Saini S, Schackman BR, Scherl E, Crawford C.  2018.  The Impact of Opioid Epidemic Trends on Hospitalised Inflammatory Bowel Disease Patients.. J Crohns Colitis. 12(9):1030-1035.
Yang A, Chen Y, Scherl E, Neugut AI, Bhagat G, Green PHR.  2005.  Inflammatory bowel disease in patients with celiac disease.. Inflamm Bowel Dis. 11(6):528-32.
Shen T-CDavid, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D et al..  2012.  Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.. J Clin Neuromuscul Dis. 13(3):137-45.
Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M et al..  2018.  Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 24(11):2461-2467.
Cohen-Mekelburg S, Schneider Y, Gold S, Ghosh G, Rosenblatt R, Hajifathalian K, Scherl E, Schnoll-Sussman F, Katz P, Steinlauf A.  2019.  Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care.. Dig Dis Sci. 64(8):2273-2279.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..  2019.  Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Koczka CPhilip, Abramowitz M, Goodman AJ.  2012.  The study of bone demineralization and its risk factors in an Afro-Caribbean subset of patients with inflammatory bowel disease.. Eur J Gastroenterol Hepatol. 24(7):759-61.
Cohen-Mekelburg S, Tafesh Z, Coburn E, Weg R, Malik N, Webb C, Hammad H, Scherl E, Bosworth BP.  2018.  Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.. Dig Dis Sci. 63(9):2439-2444.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al..  2018.  Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.
Murphy SJ, Wang L, Anderson LA, Steinlauf A, Present DH, Mechanick JI.  2009.  Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method.. Aliment Pharmacol Ther. 30(10):1078-86.